A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus nab-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer

Purpose: To evaluate safety and preliminary efficacy of metronomic 5-fluorouracil plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with newly diagnosed metastatic pancreatic cancer (MPC). Methods: A total of 12 treatment-naive patients (aged 18–65 years, Eastern Coo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Pancreat Cancer
Main Authors: Sahai, Vaibhav, Saif, M. Wasif, Kalyan, Aparna, Philip, Philip A., Rocha-Lima, Caio M., Ocean, Allyson, Ondovik, Michael S., Simeone, Diane M., Banerjee, Sibabrata, Bhore, Rafia, Louis, Chrystal U., Picozzi, Vincent
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc., publishers 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6761587/
https://ncbi.nlm.nih.gov/pubmed/31559379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/pancan.2019.0012
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados